Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2224-2233

  Klein, R Matthew ^a   Aplin, Andrew E ^a,b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; COLLAGEN GEL; DOXYCYCLINE; PHOSPHOTRANSFERASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; RND3 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN; RHOA PROTEIN, HUMAN; RND3 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE CONTROL; GENE DELETION; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; KNOCKOUT GENE; MELANOMA; MELANOMA CELL; MICROENVIRONMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRESS FIBER; TUMOR GENE; TUMOR SPHEROID; BIOSYNTHESIS; CELL CYCLE; CELL GROWTH; CELL MOTION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ACTINS; CELL CYCLE; CELL GROWTH PROCESSES; CELL MOVEMENT; CYTOSKELETON; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 65549130220     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3201     Document Type: Article

References (50)

1. Miller AJ, Mihm MC, Jr. Melanoma, N Engl J Med 2006; 355:51-65.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAE gene in human cancer. Nature 2002;417: 949-54.
3. DeLuca AM, Srinivas A, Alani RM. BRAF kinase in melanoma development and progression. Expert Rev Mol Med 2008;10:e6.
4. Sumimoto H, Miyagishi M, Miyoshi H, et al. Inhibition of growth and invasive ability of melanoma by in activation of mutated BRAF with lentivirus- mediated RNA interference. Oncogene 2004;23: 6031-9.
5. Tsai J, Lee JT, Wang W, et al. From the Cover: discovery of a selective inhibitor of oncogenic R-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105:3041-6.
6. Park S, Yeung ML, Beach S, Shields JM, Yeung KC RKIP down-regulates B-Raf kinase activity in melanoma cancer cells. Oncogene 2005;24:3535-40.
7. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserh- off A-K, Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004;64:5186-92.
8. Blackburn JS, Rhodes CH, Coon CI, Brinckerhoff CE. RNA interference inhibition of matrix metalloprotei- nase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res 2007;67:10849-58.
9. Huntington JT, Shields JM, Der Cj, et al. Over- expression of collagenase 1 (MMP-l) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 2004;279:33168-76.
10. Sahai E, Marshall Cj. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003;5:711-9.
11. Hoek KS, Eichhoff OM, Schlegel NC, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res 2008;68: 650-6.
12. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3:362-74.
13. Paszek MJ, Zahir N, Johnson KR, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005;8:241-54,
14. Hall A Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14.
15. Ridley AJ. Rho GTPases and cell migration, J Cell Sci 2001;114:2713-22.
16. Clark EA, Goluh TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC, Nature 2000;406:532-5.
17. Bellovin DI, Simpson Kj, Danilov T, et al. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006;25:6959-67.
18. Zhang C, Zhou E, Li N, et al. Overexpression of RhoE has a prognostic value in non-small cell lung cancer, Ann Surg Oncol 2007;14:2628-35.
19. Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. Oncogene 1996;13:1819-30.
20. Shields JM, Thomas NE, Cregger M, et al. Lack of extracellular signal-regulated kinase mitogen-aetivated protein kinase signaling shows a new type of melanoma. Cancer Res 2007;67:1502-12.
21. Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE. R- RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell 2008;19: 498-508.
22. Cuiyan Z, Jie H, Fang Z, et al. Overexpression of RhoE in non-small eell lung cancer (NSCLC) is associated with smoking and correlates with DKA copy number changes. Cancer Riol Ther 2007;6:335-42.
23. Bektic j, Pfeil K, Berger AP, et al. Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis. Prostate 2005;64:332-40.
24. Guasch RM, Seambler P, Jones GE, Ridley AJ. RhoE regulates actin cytoskeleton organization and cell migration. Mol Cell Biol 1998;18:4761-71.
25. Nobes CD, Lauritzen I, Mattel MG, Paris S, Hall A, Chardin P. A newf member of the Rho family, Rndl, promotes disassembly of actin filament structures and loss of cell adhesion. J Cell Biol 1998;141:187-97.
26. Aspenstrom P, Fransson A, Saras J. Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J 2004;377:327-37.
27. Chardin P. Function and regulation of Rnd proteins. Nat Rev Mol Cell Biol 2006;7:54-62.
28. Hansen SH, Zegers MMP, Woodrow M, et al. Induced expression of Rnd3 is associated with transformation of polarized epithelial cells by the Raf-MEK-Extracellular signal-regulated kinase pathway. Mol Cell Biol 2000;20: 9364-75.
29. Villalonga P, Guasch RM, Riento K, Ridley AJ. RhoE inhibits cell cycle progression and Ras-induced transformation. Mol Cell Biol 2004;24:7829-40.
30. Riento K, Totty N, Villalonga P, Garg R, Guasch R, Ridley AJ. RhoE function is regulated by ROCK l~ mediated phosphorylation. EMBO J 2005;24:1170-80.
31. Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 2007; 178:23-30.
32. Ongusaha PR Kim H-G, Boswell SA, et al. RhoE is a pro-survival p53 target gene that inhibits ROCK I- mediated apoptosis in response to genotoxic stress. Curr Biol 2006;16:2466-72.
33. Fortier M, Comunale F, Kucharczak J, Blangy A, Charrasse S, Gauthier-Rouviere C. RhoE controls myoblast alignment prior fusion through RhoA and ROCK. Cell Death Differ 2008;15:1221-31.
34. Clements RT, Minnear FL, Singer HA, Keller RS, Vincent PA. RhoA and Rho~kinase dependent and independent signals mediate TGF-β-induced pulmonary endothelial cytoskeletal reorganization and permeability. Am J Physiol Lung Cell Mol Physiol 2005;288: L294-306.
35. Boisvert-Adamo K, Aphn AE. Mutant R-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 2008; 27:3301-12.
36. Pinner S, Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 2008;10:127-37.
37. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-44.
38. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-aetivated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
39. Zamir E, Geiger B. Molecular complexity and dynamics of cell-matrix adhesions. J Cell Sci 2001;114: 3583-90.
40. Poch E, Minambres R, Mocholi E, et al. RhoE interferes with Rb inactivation and regulates the proliferation and survival of the U87 human glioblastoma cell line. Exp Cell Res 2007;313:719-31.
41. Salic A, Mitehison Tj. A chemical method for fast and sensitive detection of DKA synthesis in vivo. Proc Natl Acad Sci U S A 2008;105:2415-20,
42. Haass MK, Sproesser K, Nguyen TK, et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008; 14:230-9.
43. lecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008;20: 183-9.
44. Li N, Bait D, Warmuth M. B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 2007;8: 452-6.
45. Montagut C, Sharma Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 2008;68: 4853-61.
46. Vial E, Sahai E, Marshall Cj. ERK-MAPK signaling coordinately regulates activity of Racl and RhoA for tumor cell motility. Cancer Cell 2003;4:67-79.
47. Wennerberg K, Forget M-A, Ellerbroek SM, et al. Rnd proteins function as RhoA antagonists by activating pl90 RhoGAP. Curr Biol 2003;13:1106-15.
48. Riento K, Guasch KM, Garg R, Jin B, Ridley AJ. RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol 2003;23:4219-29.
49. Kornander D, Garg R, Wan PT, Ridley AJ, Rarford D. Mechanism of multi-site phosphorylation from a ROCK- l:RhoE complex structure. EMBO j" 2008;27:3175-85.
50. Wang L, Yang L, Luo Y, Zheng Y. A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells. J Riol Chem 2003;278:44617-25.